Pacific Biosciences of California Inc <PACB.OQ> expected to post a loss of 21 cents a share - Earnings Preview
Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to show a fall in quarterly revenue when it reports results on February 13 for the period ending December 31 2024
The Menlo Park California-based company is expected to report a 31.2% decrease in revenue to $40.16 million from $58.36 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.The company's guidance on November 7 2024, for the period ended December 31, was for revenue between $39.97 million and $40.37 million.
LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.50, above its last closing price of $1.33.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.24 | -0.22 | -0.22 | Met | 2 |
Jun. 30 2024 | -0.24 | -0.23 | -0.64 | Missed | -175.1 |
Mar. 31 2024 | -0.28 | -0.28 | -0.29 | Missed | -5.3 |
Dec. 31 2023 | -0.29 | -0.29 | -0.31 | Missed | -8.7 |
Sep. 30 2023 | -0.34 | -0.33 | -0.26 | Beat | 20.8 |
Jun. 30 2023 | -0.32 | -0.32 | -0.28 | Beat | 12.7 |
Mar. 31 2023 | -0.33 | -0.33 | -0.36 | Missed | -8.3 |
Dec. 31 2022 | -0.37 | -0.36 | -0.37 | Missed | -2.4 |
This summary was machine generated February 11 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
What to Watch in Nvidia’s Q2 FY2026 Earnings: AI Growth, Margins, and Market Impact
TradingKey - NVIDIA Corporation (NASDAQ: NVDA) will report its Q2 FY2026 earnings on Wednesday, August 27, 2025, after the U.S. market closes. The earnings call is scheduled for 5:00 p.m. Eastern Time. With Nvidia being a bellwether in AI, gaming, and data center markets, and carrying significant...
U.S. July PCE and Q2 GDP Preview: With Rate Cuts Looming, Will U.S. Stocks Continue to Rise?
TradingKey - On 28-29 August 2025, the U.S. will release July PCE and Q2 GDP data. Market expectations suggest both headline and core PCE will rise 0.3% month-over-month, consistent with June figures. For growth, in line with the preliminary estimate on 30 July, the revised Q2 annualised real GDP gr
U.S. Dollar Index: Assessing Its Future Trend Through Macro Analysis of the U.S., Eurozone, Japan, and U.K.
TradingKey - Looking ahead, in the U.S., slowing economic growth combined with ongoing interest rate cuts will exert downward pressure on the dollar. In the Eurozone, weak economic performance and continued ECB rate cuts will likely depreciate the euro, indirectly supporting the U.S. Dollar Index...
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...
